Simple pediatric AIDS severity score (PASS): A pediatric severity score for resource-limited settings

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 5, 2006, Pages 611-617

  Patel, Kunjal ^a,b   Weinberg, Geoffrey A ^c   Buchacz, Kate ^b   McIntosh, Kenneth ^d   Dankner, Wayne M ^e   Seage III, George R ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical outcomes; Pediatric AIDS; Resource limited settings; Severity score; Survival; Treatment initiation

Indexed keywords

ALBUMIN; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALBUMIN BLOOD LEVEL; ARTICLE; DISEASE SEVERITY; FEMALE; HAZARD ASSESSMENT; HEMATOCRIT; HUMAN; INFANT; KAPLAN MEIER METHOD; LOWEST INCOME GROUP; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PEDIATRIC AIDS SEVERITY SCORE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SURVIVAL RATE; SYMPTOM; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; SEVERITY OF ILLNESS INDEX;

EID: 33845368423     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000242454.97650.72     Document Type: Article

References (19)

1. UNAIDS/WHO. AIDS Epidemic Update: December 2005. Available at: http://www.unaids.org/epi/2005.
2. World Health Organization. Treating 3 Million by 2005: Making it Happen. Geneva: WHO; 2003. Available at: http://www.who.int/3by5/en/.
3. Office of the United States Global AIDS Coordinator. The President's Emergency Plan for AIDS Relief: U.S. Five-Year Global HIV/AIDS Strategy. Washington, D.C.: U.S. Department of State; 2004. Available at: http://www.state.gov/documents/organization/29831.pdf.
4. Rabkin M, El-Sadr W, Katzenstein DA, et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet. 2002;360:1503-1505.
5. Hosseinipour MC, Kazembe PN, Sanne IM, et al. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS. 2002;16(Suppl 4):S177-S187.
6. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children (November 3, 2005) Guidelines for the use of Antiretroviral Agents in Pediatric HIV Infection. Available at: http://www.aidsinfo.nih.gov/guidelines/.
7. Farmer P, Léandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 2001;358:404-409.
8. Mekonnen Y, Dukers NHTM, Sanders E, et al. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS. 2003;17:815-819.
9. Mofenson LM, Harris DR, Moye J, et al., for the NICHD IVIG Clinical Trial Study Group. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1 infected children in resource-poor settings. Lancet. 2003;362:1625-1627.
10. Gortmaker SL, Hughes M, Cervia J, et al., for the Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
11. Lindsey JC, Hughes MD, McKinney RE, et al. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline and survival in HIV-infected children. J Infect Dis. 2000;182:1385-1393.
12. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: WHO; 2003. Available at: http://www.who.int/entity/hiv/pub/prev_care/en/ arvrevision2003en.pdf.
13. Centers for Disease Control and Prevention (CDC). 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Mort Morbid Wkly Rep. 1994;43:1-10 Available at: http://www.cdc.gov/mmwr/PDF/RR/RR4312.pdf.
14. Gortmaker SL, Lenderking WR, Clark C, et al. Development and use of a pediatric quality of life questionnaire in AIDS clinical trials: reliability and validity of the General Health Assessment for Children. In: Measuring Health-Related Quality of Life in Children and Adolescents: Implications for Research and Practice. Mahwah, NJ: Lawrence Erlbaum Associates; 1998:219-235.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons; 1980:22-23, 79-81.
17. Seage GR III, Buchacz K, Weinberg GA, et al., for the Pediatric AIDS Clinical Trials Group 219 Study Team. The Pediatric AIDS Severity Score (PASS): a multidimensional AIDS-severity adjustment for pediatric HIV infection. J Acquir Immune Defic Syndr. 2006;43:603-610.
18. Harrell FE, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;2:143-152.
19. Berhane R, Bagenda D, Marum L, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics. 1997;100:e7.